Has Phillip Sandifer, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,295 in general payments to Phillip Sandifer, MD across 79 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Phillip Sandifer, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Phillip Sandifer, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Phillip Sandifer, MD

Orthopaedic Surgery · Oxford, MSNPI 1831453158

Payments from drug & device makers

What this record shows

Smith+Nephew accounts for 69.3% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2022 at $1,632 and has fallen 75.0% since, to $408 in 2025. That places this record below the midpoint for orthopaedic surgery clinicians in MS, where the typical reported total is $3,357.

$4,295in general payments, 2019–2025

Across 79 payments — averaging $54.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Smith+Nephew$3K
Orthalign Inc$320
Pacira Therapeutics, Inc.$211
Sanara Medtech Inc.$150
Bioventus LLC$108
Innovation Technologies Inc$85
plus $442 from 15 others

$74,995in ownership & investment interests, 2019–2025

Across 1 payment — averaging $74,995 each. An ownership or investment interest held by the physician or an immediate family member.

Somavac Medical Solutions, Inc.$75K

What the payments were for

Travel & lodging$1,77641%
Food & beverage$2,51959%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Smith+Nephew	35	$2,978
Orthalign Inc	3	$320
Pacira Therapeutics, Inc.	10	$211
Sanara Medtech Inc.	2	$150
Bioventus LLC	5	$108
Innovation Technologies Inc	3	$85
Medacta USA, Inc.	1	$59
KCI USA, Inc.	3	$55
Johnson & Johnson(2 entities)	2	$45
Davol Inc.	2	$38
Heron Therapeutics, Inc.	2	$38
Medtronic	2	$32
Si-bone, Inc.	1	$27
Convatec Inc.	1	$25
Boston Scientific	1	$22
Pacira Pharmaceuticals Incorporated	1	$19
Ferring Pharmaceuticals Inc.	1	$18
Endo Pharmaceuticals Inc.	1	$18
Vertex	1	$17
Abbott	1	$16
Stryker	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,295 in reported general payments places this provider in the 50th percentile of 170 orthopaedic surgery providers in Mississippi.

See all orthopaedic surgery providers in Mississippi →

Medicare billing

Part B allowed, 2024

$481,600

Medicare patients

606

Services billed

5,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Celecoxib	879	$16,215
Pregabalin	178	$2,270
Methocarbamol	311	$2,029
Ondansetron OdtOndansetron	239	$1,943
Oxycodone Hcl	240	$1,417
Tramadol Hcl	335	$1,130
Gabapentin	133	$941
Doxycycline Hyclate	46	$783
Methylprednisolone	107	$711
Prednisone	250	$551
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	45	$322
Ibuprofen	26	$230
Meloxicam	47	$117
Amoxicillin	12	$7

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Oxford

Allen MooreOxford$21K
Robert EllisOxford$17K
Matthew GravesJackson$1.2M
George van OstenTupelo$322K
Edward HobgoodJackson$267K
Hanna MitiasNew Albany$249K
Stephen SouthworthTupelo$160K
Jamey BurrowJackson$130K
Jeff AlmandJackson$109K
Spencer MontgomeryJackson$90K

See the full list for Mississippi →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →